EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel: A phase II study



Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel: A phase II study



Cancer Chemotherapy & Pharmacology 39(1-2): 150-156



Vinorelbine (VNB) shows high antitumoral activity in advanced breast cancer due to its high affinity for mitotic tubulin and differs from the other vinca alkaloids with regard to its low degree of neurotoxicity because of its low affinity for axonal tubulin. Preclinical data show the existence of different binding sites on tubulin for vinca alkaloids and paclitaxel (P), suggesting a lack of cross-resistance. Thus, VNB was chosen eligible for a phase II study to evaluate both the therapeutic efficacy and the toxicity of VNB in patients (pts) with advanced breast cancer failing first- or second-line chemotherapy with P. A total of 14 pts with advanced breast cancer pretreated with P were entered into the study. Therapy consisted of VNB at 30 mg/m-2 diluted in 500 ml of normal saline given over 30 min after a minimal interval of 4 weeks since the last application of P. For the first four cycles, injections were repeated at 2-week intervals; thereafter they were repeated at 3-week intervals until evidence of progressive disease or severe toxicity developed. All but one pt was considered assessable for response and all pts were evaluable for toxicity. No objective response was observed; two pts showed no change in their disease. In four pts therapy had to be stopped because peripheral neuro- toxicity increased from a pretherapeutic level after therapy with P from National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade 1 (n = 3) and 2 (n = 1) to neurotoxicity grade 3 after 1, 2 (n = 2), and 3 cycles of therapy with VNB, respectively. In addition, constipation of grade 2 occurred in 10 pts. Hematologic toxicity was negligible. No other evaluable toxicity exceeded NCI-CTC grade 1. Both observations of this study, the complete resistance to VNB and the increase in peripheral neuropathy, let us assume the existence of a preclinically not anticipated but clinically relevant cross-resistance between these two spindle poisons and the presence of common functional targets. Therefore, P-pretreated pts should be excluded from consecutive VNB-containing therapies.

(PDF emailed within 0-6 h: $19.90)

Accession: 009724609

Download citation: RISBibTeXText

PMID: 8995513

DOI: 10.1007/s002800050551



Related references

Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients. Seminars in Oncology 23(5 Suppl 11): 38-40, 1996

Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study. Annals of Oncology 7(8): 857-860, 1996

Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. Journal of Clinical Oncology 12(10): 2094-2101, 1994

Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer. American Journal of Clinical Oncology 27(3): 317-321, 2004

Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer. Oncology 62(2): 103-109, 2002

A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients. International Journal of Oncology 42(5): 1778-1785, 2013

Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. Cancer ChemoTherapy and Pharmacology 58(6): 742-748, 2006

Phase I study with weekly paclitaxel infusion in heavily pretreated advanced breast cancer and ovarian cancer patients. Onkologie 18(SUPPL 2): 100, 1995

Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. British Journal of Cancer 90(9): 1740-1746, 2004

Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study. Clinical Lung Cancer 12(2): 100-105, 2011

Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study. Lung Cancer 53(1): 85-90, 2006

A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. Anti-Cancer Drugs 17(9): 1067-1073, 2006

Activity and feasibility of a ten-day schedule of single agent vinorelbine in advanced, pretreated breast cancer A phase II study. European Journal of Cancer 37(Supplement 6): S195-S196, October, 2001

A phase I study. UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer. Oncology 14(10 Suppl 9): 44-46, 2000